Odevixibat (Bylvay) study for PFIC patients in South Korea
Part of Digestive system clinical trials.
This study is tracking how well odevixibat (Bylvay) works and how safe it is for people with progressive familial intrahepatic cholestasis (PFIC) in South Korea. It is for patients who are already prescribed this medicine by their doctor, and it monitors their progress over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with PFIC (any type).
- Your doctor has prescribed odevixibat (Bylvay) for you, separate from this study.
- You are currently taking odevixibat or will start taking it soon.
- You are not in another clinical trial for PFIC or using odevixibat through another study.
- You have no known reason (contraindication) that would make odevixibat unsafe for you, as listed in the South Korean product label.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with PFIC (a rare liver disease affecting bile flow) who are taking or planning to take odevixibat (Bylvay), a medication that helps manage the condition. Researchers will track how well the medication works, any side effects, and long-term health outcomes in Chinese patients.
This study tracks treatments and outcomes for people with a confirmed genetic form of PFIC, a rare liver disease. It helps doctors learn which treatments work best for each type.
This study looks at different genetic liver conditions called PFIC and follows how they progress over time. It also studies whether a procedure called biliary diversion may improve symptoms or long-term outcomes.
This study looks at the long-term safety and effects of Livmarli (maralixibat) in children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC). It may help understand how well the medicine works over time for itching and other symptoms.
This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.
This study collects information on how well Imjudo and Imfinzi work in real-world settings for patients who are prescribed these drugs as part of standard care in South Korea. It helps doctors understand how these treatments perform outside of clinical trials.
Hear when a new Progressive Familial Intrahepatic Cholestasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.